Enhancement of an advanced clinical trial recruitment platform for Europe to ensure maximum intake of eligible consenting patients for participation

Información del proyecto

CliniTrial

Identificador del acuerdo de subvención: 745469

DOI

10.3030/745469

Proyecto cerrado

Fecha de la firma de la CE 23 Noviembre 2016

Fecha de inicio 1 Noviembre 2016

Fecha de finalización 30 Abril 2017

Financiado con arreglo a

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coste total

€ 71 429,00

Aportación de la UE

€ 50 000,00

Coordinado por

VIOMEDO UG (HAFTUNGSBESCHRANKT)
Germany

Objetivo

Many patients can’t effectively be treated with the standard of care today. They suffer from their diseases that can’t be managed or cured. Newly developed therapies represent their only hope.
Unfortunately, it takes ever more time and money to bring innovative therapies to market. A major challenge in clinical development is finding the right patients to participate in clinical trials. The problem is that patients lack access to trials.
The online platform viomedo supports patients with finding the right clinical trial for them, while helping the organizations that run trials, such as pharmaceutical companies, recruit patients more efficiently. The disruptive solution provides access to over 2.000 up-to-date clinical trials that are recruiting patients in Germany. Patients, care givers or doctors can easily search for a trial by disease, confirm their eligibility and contact the investigator.
Patients want to be increasingly involved in deciding which therapy to choose. 75% of them are interested in learning about clinical trial opportunities. Most turn mainly to the internet for health-related information. However, a patient-centric online platform for clinical trials is missing. Viomedo empowers patients by providing this platform.
Important milestones – such as the development of a public beta version of the platform, collaboration with leading patient advocacy groups, acquisition of six large pilots with pharmaceutical companies – have been reached. The goal of phase 1 is to complete the pilot projects and develop an EU-wide rollout strategy. After the business case is ready and validated, viomedo will be rolled out to major European markets in phase 2.
Once viomedo is rolled out to all European patients, it will help more patients benefit from the research earlier. It will also make the EU a more attractive region for conducting research. It will help bring patient centricity and openness into the industry, raising the quality of clinical research conducted.

Ámbito científico (EuroSciVoc)

• ciencias naturales › informática y ciencias de la información › internet
• ciencias naturales › informática y ciencias de la información › seguridad informática › protección de datos
• ciencias sociales › sociología › gobernanza › gestión de crisis

Programa(s)

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being PROGRAMA PRINCIPAL
  
• H2020-EU.3.1.4. - Active ageing and self-management of health
  
• H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)
  
• H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
  
• H2020-EU.3.1.6. - Health care provision and integrated care
  

Tema(s)

• SMEInst-06-2016-2017 - Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well
  

Régimen de financiación

SME-1 - SME instrument phase 1

Convocatoria de propuestas

H2020-SMEInst-2016-2017

Coordinador

VIOMEDO UG (HAFTUNGSBESCHRANKT)

• Aportación neta de la UEn: € 50 000,00
• Dirección: LAUSITZER STRASSE 18 ; 10999 BERLIN ; Alemania
• Pyme Sí:
  Región
  Berlin › Berlin › Berlin
• Región: Berlin › Berlin › Berlin
• Tipo de actividad: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Coste total: € 71 429,00